NASDAQ OMX

Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology

Dela

Press Release

10 November 2017

Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology

Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced two online publications of preclinical studies investigating the mode of action of lead program ilixadencel in the prestigious scientific journal Oncoimmunology . The studies show the multiple ways in which ilixadencel, or corresponding allogeneic proinflammatory mouse dendritic cells, create an immune-priming environment. Excerpts of the in vitro study were recently presented in a poster at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual Meeting http://bit.ly/2zq2eBZ .

The publications in Oncoimmunology conducted in collaboration with Professor Magnus Essand's research group at Uppsala University, showed the following:

  • Ilixadencel addresses several key complementary immunological mechanisms to increase the capacity of the immune system to more efficiently recognize and destroy tumor cells.
  • Additional data from the cell culture studies demonstrated that ilixadencel boosts the ability of bystander dendritic cells (corresponding to the patients dendritic cells) to capture, process and present released tumor antigens leading to a subsequent activation of tumor-specific cytotoxic T-cells, which are important in the effective long-term destruction of tumor cells.
  • In the mouse tumor models, researchers were able to show that a local subcutaneous injection of allogeneic proinflammatory mouse dendritic cells (alloDCs) induced migration of activated host dendritic cells to the draining lymph node. Intratumoral injection of alloDCs furthermore altered the immunosuppressive tumor micro-environment in these mice resulting in a pro-inflammatory milieu that led to the recruitment of NK cells and CD8+ T cells to the treated tumor.

"The new data that now has been published, show the ability of ilixadencel, and corresponding allogeneic proinflammatory mouse dendritic cells, to stimulate several very important mechanisms to induce tumor-specific immune responses," said Alex Karlsson-Parra, Chief Scientific Officer of Immunicum. "The results further underscore the impact our technology could have in modern cancer treatment regimens and is in line with the promising signs of efficacy we have seen in the clinical trials with ilixadencel."

As part of the expanded data on ilixadencel's mode of action, the two studies also investigated the novel approach Immunicum is evaluating for potential subcutaneous injection in certain types of tumor diseases. This approach is based on the same principles as for ilxadencel with the addition of Immunicum's proprietary adenovirus vector Ad5PTDf35 used for transfection of ilixadencel with genes coding for tumor-specific antigens. Using this model, the researchers could replicate the immune system priming effect seen with non-transfected ilixadencel in vitro and mouse alloDC in vivo. Additional studies are needed to investigate the benefits and the safety profile to define the capabilities of this novel approach and how it could complement Immunicum's pipeline.

Immunicum's lead program ilixadencel has been tested in over 85 patients to date. Completed Phase 1/2 studies in renal cell carcinoma and hepatocellular carcinoma have shown a favourble  safety profile and initial signs of efficacy. There is  clinical development ongoing in a Phase 2 trial in renal cell carcinoma (MERECA) as well as a Phase 1/2 study in gastrointestinal stromal tumors (GIST).

The full publications titled "Pro-inflammatory allogeneic DC's promote activation of bystander immune cells and thereby license antigen specific T-cell responses" and "Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs lead to sustained antigen-specific immune responses in three melanoma models" can be accessed through the current online version of Oncoimmunology and the following link. http://bit.ly/2j9pePF

About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX®) is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: ir@immunicum.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Northland Power Announces Retirement of CEO John Brace and Appointment of Mike Crawley as Chief Executive Officer, Effective August 4, 201823.5.2018 01:27Pressmeddelande

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that Chief Executive Officer John Brace will retire on August 4, 2018 after 30 years with the company. Mike Crawley, currently Northland's Executive Vice President, Development has been appointed to the role of Chief Executive Officer, effective August 4, 2018. Mr. Brace and Mr. Crawley will work together to ensure a smooth transition. Mr. Brace will continue to serve as a Director of Northland. John joined Northland in 1988, shortly after the company was founded. He was appointed Chief Executive Officer in 2005. He has steered Northland through many of its projects, initiatives and growth. Under his leadership, the company has grown to its current enterprise value of $12 billion. John was appointed to Northland's Board of Directors on April 4, 2018, and along with Northland's other board members, will stand for re-election at Northland's Annual General Meeting on May 23rd, 2018. Mike

MyoGen: Leaders of an Anabolic Revolution22.5.2018 23:00Pressmeddelande

GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of. To be an athlete means to partake on a never-ending quest for self-improvement. An obsession to search for a winning edge. Even when we are competing against ourselves, our desire to overcome our physical limitations and achieve new heroic and record setting performances becomes an overwhelming primary focus. Today marks an evolution in what the human body is capable of, with the launch of the MyoGen range of anabolic products. Myogen, the essence of "muscles". MyoGen takes its source from the Greek words "Myo" meaning "Muscle" and "Genesis" meaning "Birth". This implicit historical reference, of the origin of the muscle, displays both the commitment and professionalism of Myogen, and their unwavering focus on peak physical performance. The brightest leader's blaze trails. The Myogen brand is managed by an international team of experts who are committed to making athletes st

Constellation Brands Promotes Jim Sabia to Newly Created Role of Chief Marketing Officer22.5.2018 22:30Pressmeddelande

New role will serve as a member of the company's Executive Management Committee VICTOR, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that it has promoted Jim Sabia to the newly created role of Executive Vice President and Chief Marketing Officer, Constellation Brands. In this new role, Sabia will serve as the marketing lead for the company's Beer and Wine & Spirits Divisions, responsible for all aspects of marketing across Constellation's entire beverage alcohol portfolio. Sabia will serve as a member of the company's Executive Management Committee and report directly to Bill Newlands, President and Chief Operating Officer. "Our company's core mission is to build brands consumers love and Jim has been a driving force behind the success of our beer brands over the years," said Newlands. "It is critically important that the voice of the consumer and brand-building principles have strong repr

Algeco Announces First Quarter 2018 Financial Results Conference Call22.5.2018 17:52Pressmeddelande

BALTIMORE, May 22, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, "Algeco"), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its first quarter 2018 financial results conference call on Tuesday, June 5, 2018 at 10:00 a.m., Eastern Time. To access the call, please dial (847) 585-4422 or (888) 424-8151 (US toll free) and enter participant PIN code 9192211# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to http://web.meetme.net/r.aspx?p=2&a=UTzMrdwdRriEIu. Please enter your name, email address and company to join the call. The customer service team can be reached at any time by pressing *0 on your telephone keypad. On Wednesday, May 30, 2018 at

Hitachi Named a Visionary in Inaugural Gartner Magic Quadrant for Industrial IoT Platforms22.5.2018 15:00Pressmeddelande

Hitachi Positioned in Visionaries Quadrant for Completeness of Vision and Ability To Execute TOKYO and SANTA CLARA, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) and Hitachi Vantara, today announced that Hitachi has been positioned in the Visionaries quadrant of the inaugural Gartner Magic Quadrant for Industrial IoT Platforms1based on Gartner, Inc.'s evaluation of the company, which included Hitachi's Lumada IoT platform. Gartner describes the market for IIoT platforms as "a set of integrated software capabilities. These capabilities span efforts to improve asset management decision-making, as well as operational visibility and control for plants, depots, infrastructure and equipment within asset-intensive industries." In the report, Gartner predicts: "By 2020, on-premises Internet of Things (IoT) platforms coupled with edge computing will account for up to 60% of industrial IoT (IIoT) analytics, up from less than 10% today." The report also notes: "Gartner believe

Cemtrex SmartDesk Now Available for Preorder22.5.2018 14:30Pressmeddelande

Cemtrex Launches SmartDesk to Reinvent the Personal Workspace and Revolutionize Desktop Workstation Productivity FARMINGDALE, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Cemtrex Inc. (Nasdaq:CETX) (Nasdaq:CETXP) (Nasdaq:CETXW), a world leading technology and manufacturing company, today announced the launch of the Cemtrex SmartDesk, the most advanced workstation on the market. The SmartDesk is a blend of futuristic hardware and groundbreaking productivity software, delivering the next generation desktop experience in a luxurious package, and Cemtrex is now taking preorders. "The world is ready for a SmartDesk. It is 2018 but our workspaces have not evolved like most things we interact with on a daily basis like our smartphones, smart cars and smart homes," said Cemtrex's CEO and Chairman, Saagar Govil. "With the SmartDesk we intend to transform and disrupt the $500 billion annual PC market globally, as it will streamline workflows, improve productivity with its many features, and provide su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum